Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis
- 9 February 2007
- journal article
- clinical trial
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 13 (6), 754-762
- https://doi.org/10.1177/1352458506074510
Abstract
Objective To determine whether glatiramer acetate (GA)-induced lymphoproliferation and IFN-γ and IL-4 modulation correlate with the clinical response in multiple sclerosis (MS).Keywords
This publication has 29 references indexed in Scilit:
- Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-b1a or glatiramer acetate compared with untreated patientsMultiple Sclerosis Journal, 2003
- Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotypeJournal of Neuroimmunology, 2003
- Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitisJournal of Clinical Investigation, 2002
- Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MSMultiple Sclerosis Journal, 2001
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cellsMultiple Sclerosis Journal, 2001
- Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1Proceedings of the National Academy of Sciences, 2000
- Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosisJournal of Clinical Investigation, 2000
- The development of Cop 1 (Copaxone®), and innovative drug for the treatment of multiple sclerosis: personal reflectionsImmunology Letters, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995